{"entity":{"id":"nct03096093","kind":"trial","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","aka":[],"tldr":"A phase 1/2 trial of ACIT-1 in advanced solid tumours, run by Cancer Vaccines Limited, active and no longer recruiting.","summary":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer is a phase 1/2 interventional study registered as NCT03096093 by Cancer Vaccines Limited, with 34 participants enrolled, started 2017-04-25 and due to reach its primary completion in 2026-12. Interventions recorded: ACIT-1.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03096093","url":"https://clinicaltrials.gov/study/NCT03096093"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03096093","phase":"1/2","setting":"A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients","sponsor":"Cancer Vaccines Limited","enrolled":34,"outcomes":[]},"route":"/trials/nct03096093/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}